Doer Biologics Announced First Patient Dosed in Phase 2 Study of DR10624, reported by mainstream media

Recently,many mainstream media forwarded the "Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia" released by CISION PR on September 30, 2024, following are some news links:

AP NEWS、Benzinga、KTLA、PR Newswire、Seeking Alpha